Gretai:6535

Lumosa Announces FDA Acceptance of IND Application for LT1001, an Extended-Release Analgesic Injection - Lumosa to Initiate the Bridging Study in the US

TAIPEI, Dec. 3, 2019 /PRNewswire/ -- Opioid misuse, addiction, and overdoses have caused significant social and economic burdens leading to the opioid crisis. LT1001 (brand name Naldebain®) is a prodrug of nalbuphine, an abuse-free analgesic that has been marketed worldwide for decades. Naldebain...

2019-12-03 17:36 214

Lumosa to Initiate Phase 2 Human Clinical Trial in the US and Taiwan for Its LT3001, A Novel Drug for the Treatment of Acute Ischemic Stroke

TAIPEI, , June 13, 2019 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; code: 6535.TWO) announced that the company is ready to commence the Phase 2 proof of concept (PoC) study for its LT3001, a novel drug for the treatment of acute ischemic stroke (AIS) that showed good safety, tolerability and ...

2019-06-13 20:00 3831

Lumosa Therapeutics Licenses Long Acting Injectable Analgesic to Skyline Vet Pharma, Inc. for Use in Companion Animals

TAIPEI, and GROTON, Conn., Jan. 16, 2018 /PRNewswire/ -- Lumosa Therapeutics (Lumosa, 6535.TWO), a new drug development company inTaiwan, and Skyline Vet Pharma (SVP), an emerging animal health company in theUSA, today announced a licensing agreement for Lumosa's CS011.According to the terms, SV...

2018-01-16 18:22 370

First Human Subject Enrolled in Lumosa Therapeutics' Phase 1 Trial for LT3001, a New Drug Molecule for Acute Ischemic Stroke

TAIPEI, , July 31, 2017 /PRNewswire/ -- Lumosa Therapeutics Co., Ltd., (TPEx: 6535, hereinafter 'Lumosa') is pleased to announce the enrollment of the first subject for the Phase 1 clinical trial of its new drug candidate, LT3001, for acute ischemic stroke. The first human subject was dosed wi...

2017-08-01 09:46 1548